FUS and amyotrophic lateral sclerosis: Recent publications detecting higher levels of a subset of SOD1 antibodies in long-term survivor ALS patients [46], misfolded SOD1 in sALS [7], [9], and SOD1 misfolding when FUS and TDP43 are mislocalized [47] provide evidence that SOD1 has potential as a therapeutic target in fALS and sALS.